8-K: KORU Medical Systems Announces Departure of Chief Commercial Officer and Reaffirms 2025 Revenue Guidance

KORU Medical Systems announces the resignation of its Chief Commercial Officer, Kenneth Miller, effective immediately, and reaffirms its full-year 2025 revenue guidance of $38.0-$39.0 million.

Summary

• KORU Medical Systems announced the resignation of Kenneth Miller, Chief Commercial Officer, effective April 3, 2025.
• Miller is leaving to take a CEO position at a non-competing organization.
• Rob Cannon, Vice President of Sales for North America, will lead commercial operations for the Core business until a new CCO is appointed.
• The company has retained an executive search firm to find a new Chief Commercial Officer.
• KORU Medical is reiterating its full-year 2025 revenue guidance of $38.0-$39.0 million, which was initially issued on March 12, 2025.
• The announcement includes forward-looking statements subject to risks and uncertainties outlined in the company's SEC filings.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the departure of a C-level executive is a concern, the company has a plan in place and reaffirmed its revenue guidance, suggesting stability.

Positives

• KORU Medical has a ready replacement in Rob Cannon to lead commercial operations during the search for a new CCO.
• The company is actively seeking a replacement CCO through an executive search firm.
• Reaffirmation of the full-year 2025 revenue guidance provides stability and predictability for investors.

Negatives

• The departure of the Chief Commercial Officer could create uncertainty in the company's commercial strategy and execution.

Risks

• The company's forward-looking statements are subject to various risks and uncertainties, including SCIg market growth, prefilled syringe penetration, plasma supply, clinical trial activity, new drug approvals, healthcare delivery shifts, new patient diagnoses, customer ordering patterns, global health crises, innovation, competition, labor and supply price increases, inflationary impacts, and labor supply.
• Failure to find a suitable replacement for the CCO in a timely manner could negatively impact commercial operations.

Future Outlook

KORU Medical reiterates its full-year 2025 revenue guidance of $38.0-$39.0 million, but actual results may differ materially due to various risks and uncertainties.

Management Comments

• KORU Medical would like to thank Mr. Miller for his contributions to the Company and recognize the instrumental role he played in establishing and implementing strategic commercial growth priorities during his tenure.

Industry Context

The announcement comes amid ongoing shifts in healthcare delivery towards home-based care, which is a key market for KORU Medical's infusion solutions. The company's performance is also influenced by factors such as SCIg market growth, prefilled syringe penetration, and plasma supply.

Management Changes

Stakeholder Impact

• Shareholders may experience short-term uncertainty due to the executive departure.
• Employees in the commercial operations team may experience a temporary shift in leadership.
• Customers may not experience any immediate impact, as Rob Cannon will lead commercial operations during the transition.

Next Steps

• KORU Medical will continue the search for a new Chief Commercial Officer.
• Rob Cannon will lead commercial operations for the Core business until a new CCO is named.

Key Dates

Keywords

KORU Medical, Chief Commercial Officer, revenue guidance, resignation, commercial operations, executive search, SCIg, financial guidance